高血压病人血浆ADM、ET-1及VWF含量的检测

①目的　观察原发性高血压 (EH)不同危险度分层病人血浆肾上腺髓质素 (ADM)、内皮素 1(ET 1)及假性血友病因子 (VWF)含量变化及其临床意义。②方法　随机选取不同危险度分层高血压病人 80例 ,分别测定治疗前后血浆ADM、ET 1、VWF含量的变化 ,并与 2 0例正常人测定结果比较。③结果　治疗前不同危险度分层高血压病人血浆ADM、VWF、ET 1含量均高于对照组 ,差异有显著性 (F =6 .2 3～ 17.0 8,q =4 .2 7～ 10 .4 3,P <0 .0 5 ) ,且随危险度增加而增高 (q=3.87～ 6 .86 ,P <0 .0 5 ) ;ADM含量与VWF、ET 1含量呈正相关 (γ =0 .6 0 2、0 .6 83,P <0 .0 1)。治疗后各组ADM、VWF、ET 1含量较治疗前降低 ,差异有显著性 (t=3.71～ 2 0 .80 ,P <0 .0 1)。④结论　ADM、VWF、ET 1参与了高血压的发生发展 ,正规有效治疗可降低ADM、ET 1、VWF的水平。

A DETECTION OF PLASMA ADRENOMEDULLIN ENDOTHELIN-1, AND VON WILLEBRAND FACTOR IN PATIENTS WITH HYPERTENSION

Objective To study the relationship between the risk stratification in essential hypertension(EH) and the levels of plasma VWF, ADM and ET 1, and explore the clinic significance. Methods Eighty EH patients with different risk stratification were randomly selected for this study. The plasma VWF,ADM and ET 1 were detected and compared with 20 normal controls. Results Before treatment ,the levels of plasma VWF, ET 1, ADM increased significantly in EH group compared to that of the control group, the difference was significant ( F=6.23-17.08, q=4.27-10.43, P <0.05), and the levels of VWF, ET 1 And ADM elevated with the increase of the risk ( q=3.87-6.86, P <0.05). The levels of ADM, ET 1 and VWF were lower than that of before treatment, the difference showed great difference ( t= 3.71-20.8, P <0.05). Conclusion ADM, ET 1 and VWF are involved in the occurrence and development of essential hypertension. Proper therapy can lower the levels of ET 1, ADM and VWF.